The rapid acceleration of drug development has exponentially increased the therapeutic options available to patients with cancer.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
Single-country clinical trial results: Are they applicable to other populations?
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Physician-in-Chief, Orange County; Vice Physician-in-Chief, City of Hope National Medical Center
Table of Contents
YOU MAY BE INTERESTED IN
The University of Texas MD Anderson Cancer Center launched its Institute for Cell Therapy Discovery & Innovation.
J. Leonard Lichtenfeld joined SpotitEarly, an Israel-based technology company transforming cancer screening by harnessing the power of artificial intelligence and dogs to detect cancer early, as chief medical officer.
NIH Director Monica M. Bertagnolli delivered the Charles G. Moertel Lecture at the Fall Group Meeting of the Alliance for Clinical Trials in Oncology. The meeting took place Oct. 30-Nov. 1.
A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer.
Promising preliminary results from an ongoing investigator-initiated phase I clinical trial evaluating the safety and efficacy of a combined regimen of Keytrua (pembrolizumab) and Lymphir (denileukin diftitox-cxdl or E7777) in patients with recurrent solid tumors were announced.
